Arrowhead Pharmaceuticals, Inc. (ARWR)

Revenue

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
GSK Revenue	-	2.65M	2.69M
GSK Revenue Growth	-	-1.49%	-90.95%
Takeda Revenue	-	-	866.00K
Takeda Revenue Growth	-	-	-99.47%
Sarepta Revenue	425.30M	696.80M	-
Sarepta Revenue Growth	-38.96%	-	-
Sanofi Revenue	-	130.00M	-
Revenue (Other)	196.71M	-	-
Revenue (Total)	622.01M	829.45M	3.55M
Revenue (Total) Growth	-25.01%	23258.15%	-98.52%

Data Source: Fiscal.ai Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 22, 2026

Data Sources Report a data error